Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease
The DOI matches its Crossref record; 282 of the 287 references it cites were found in a registry or an index.
Abstract
There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme reduce Aβ levels and protect against cognitive impairment in mouse models of AD. The activity of several Aβ-degrading enzymes rises with age and increases still further in AD, perhaps as a physiological response to minimize the buildup of Aβ. The age- and disease-related changes in expression of more recently recognized Aβ-degrading enzymes (e.g. NEP-2 and cathepsin B) remain to be investigated, and there is strong evidence that reduced NEP activity contributes to the development of cerebral amyloid angiopathy. Regardless of the role of Aβ-degrading enzymes in the development of AD, experimental data indicate that increasing the activity of these enzymes (NEP in particular) has therapeutic potential in AD, although targeting their delivery to the brain remains a major challenge. The most promising current approaches include the peripheral administration of agents that enhance the activity of Aβ-degrading enzymes and the direct intracerebral delivery of NEP by convection-enhanced delivery. In the longer term, genetic approaches to increasing the intracerebral expression of NEP or other Aβ-degrading enzymes may offer advantages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“through the production of various Aβ degrading enzymes, such as insulin-degrading enzyme (IDE), neprilysin (NEP), and MMP9, which may be secreted to degrade Aβ extracellularly [146–148]”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [146]
In the citing paper
“The Aβ degradation is ensured by some proteases, such as cathepsin and the insulin-degrading enzyme (IDE), which cleave the Aβ into smaller soluble fragments (Miners et al., 2011; Kurochkin et al., 2018).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Miners et al., 2011
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedPulukuri, S. M. K., Estes, N., Patel, J., & Rao, J. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2892 · Cited by 84 · cited 1×
“Several findings highlight the potential therapeutic use of valproate in AD (236): not only does it upregulate NEP, it also upregulates plasmin (237), and its safety and efficacy have been extensively documented in the treatment of epilepsy and psychosisYrelated behavioral problems (238).”
BackgroundRetractedAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“Recent studies indicate that environmental stimuli largely determine whether microglia adopt a phagocytic ‘‘protective’’ response or a damaging ‘‘neurotoxic’’ response (205, 206) and that a proinflammatory response is associated with reduced microglial phagocytosis (207).”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“Recent studies indicate that environmental stimuli largely determine whether microglia adopt a phagocytic ‘‘protective’’ response or a damaging ‘‘neurotoxic’’ response (205, 206) and that a proinflammatory response is associated with reduced microglial phagocytosis (207).”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Recent research suggests strongly that clearance rather than production of AA is impaired in late-onset sporadic AD (7).”
BackgroundJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · cited 9×
“The direct toxicity of not only AA1Y40 and AA1Y42 but also their degradation products, therefore, likely depends on how they combine to form assemblies in vivo because conversion from oligomers to protofibrils to fibrils is associated with a reduction in directly mediated damage to synapses and neurons (77).”
BackgroundInfluential
Research works printed but not linked: 3
- 10.1042/bst0331101 · doi:10.1042/bst0331101 · Paper page
- 10.1097/64.5.378 · doi:10.1097/64.5.378
- 10.1097/62.9.885 · doi:10.1097/62.9.885
Cited by
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Self-citationMicroglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Microglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618
Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes
Katsuda, T., Tsuchiya, R., Kosaka, N., Yoshioka, Y., Takagaki, K., Oki, K., Takeshita, F., Sakai, Y., Kuroda, M., & Ochiya, T. (2013) · Scientific Reports · doi:10.1038/srep01197 · Cited by 565
Metadata
- Authors
- Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S.
- Affiliations
- Frenchay Hospital (GB)
- Corresponding author
- Miners, James Scott
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 70
- Issue
- 11
- Pages
- 944-959
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1994344429
- Cited by
- 265
- References
- 287
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 23 · 2016: 32 · 2015: 14 · 2014: 31 · 2013: 24 · 2012: 20
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Funders
- James Tudor Foundation
- Engineering and Physical Sciences Research Council (EP/G061866/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid-beta, Alzheimer's disease, neprilysin, insulin-degrading enzyme, endothelin-converting enzyme, cathepsin B, cerebral amyloid angiopathy, amyloid clearance, convection-enhanced delivery, gene therapy, cognitive impairment
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Glycopeptides, Humans, Insulysin, Mice, Transgenic, Protease Inhibitors, Thiorphan, Neprilysin, Genetic Therapy, Amyloid beta-Peptides, Microglia, Stem Cell Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. https://app.cochat.ai/papers/10.1097/nen.0b013e3182345e46
- The paper
- Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011). Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e3182345e46
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.